+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gemcitabine Hydrochloride Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • PDF Icon


  • 117 Pages
  • April 2023
  • Region: Global
  • Mordor Intelligence
  • ID: 4997541
UP TO OFF until Mar 31st 2024
The Gemcitabine Hydrochloride Market is expected to register a CAGR of 7.1% during the forecast period.

COVID-19 pandemic had a substantial impact on patients with underlying diseases; gemcitabine was shown to have both anti-cancer and anti-viral activity. For instance, the NCBI article published in February 2021 suggested that gemcitabine's difluoro group is essential for the antiviral action and its combination with other antiviral medications that have been studied, including remdesivir, may be a desired alternative for treating SARS-CoV-2 infection. Thus, such potential benefits of gemcitabine had a notable impact on the demand for gemcitabine hydrochloride, ultimately impacting the market growth during the pandemic period. In addition, the demand for gemcitabine is expected to remain intact during the post-pandemic period, thereby contributing to the market's growth over the forecast period.

The gemcitabine hydrochloride market is expected to grow during the forecast period due to the significantly increased prevalence of cancer prevalence globally owing to the rising usage of gemcitabine with other drugs in the treatment of cancer. Further, increased awareness about cancer and patient support programs are among the major factors driving the growth of the studied market. According to the World Health Organization factsheet published in February 2022, in 2021, an estimated 1.9 million new cancer cases were diagnosed in the United States. The report also mentioned that each year, approximately 400,000 children develop cancer globally. Cervical cancer is the most common in 23 countries, such as Eswatini, India, South Africa, Latin America, and others. The most common cancers are breast, lung, colon and rectum, and prostate cancers. Thus, the high burden of cases of cancer is generating the demand for effective treatment options such as gemcitabine owing to the potential usage with other drugs in the treatment of cancer, thereby contributing to the growth of the market over the forecast period.

Additionally, the increasing product developments by key market players and product approvals are expected to contribute to the market's growth. For instance, in September 2022, Syros Pharmaceuticals received FDA orphan drug designation for the product SY-5609, a CDK7 inhibitor, in combination with chemotherapy for patients with relapsed metastatic pancreatic cancer. The clinical initiated regarding the product, the participants are assigned to SY-5609 plus gemcitabine at approved doses. Therefore, owing to the aforementioned factors, such as rising cancer cases, increasing demand for effective therapeutics, along with increasing product developments, the studied market is anticipated to witness growth over the analysis period. However, the stringent regulatory framework is likely to impede the market growth.

Gemcitabine Hydrochloride Market Trends

Lung Cancer is Expected to Witness Significant Growth Over the Forecast Period

The lung cancer segment is expected to hold a significant share in the growth of the market owing to the high prevalence of lung cancer cases and rising demand for the growth of effective treatment for lung cancer.

For instance, in the Lung Cancer Foundation data published in 2022, an estimated 236,74 people were diagnosed with lung cancer in the United States, 2022. Additionally, the NCBI article published in January 2022 mentioned that the incidence of lung cancer among the non-smoker female population was 17.1 per 100,000 in 2022. The article also mentioned that non-smoker Chinese American females and the highest rate of cancer which was 22.8 per 100,000 in 2021. Such increasing incidence of lung cancer among the global population is expected to drive the demand for effective treatment, thereby driving segment growth.

Likewise, the research studies proving the efficacy of gemcitabine in the treatment of lung cancer are also expected to drive segment growth. For instance, according to an article published in the National Library of Medicine in August 2021, combination therapy of gemcitabine with a platinum agent is a highly effective treatment among the platinum doublet regimens. It is promising as a treatment for advanced squamous cell lung carcinoma. Thus, such research activities will lead to verticle growth in the coming future. On the other hand, the rising product developments and clinical trials by various market players are also expected to contribute to the market's growth. For instance, in August 2022, Ipsen Announced results from the phase III resilient trial evaluating Onivyde in second-line monotherapy for small lung cancer. Onivyde is approved in combination with fluorouracil and leucovorin for the treatment of patients following gemcitabine-based therapy.

Thus, the high prevalence of lung cancer, research and development associated with lung cancer, and lower side effects of gemcitabine are expected to boost the growth of the studied segment over the forecast period.

North America is Expected to Hold Significant Share in the Market over the Forecast Period

North America is expected to hold a major market share in the global gemcitabine hydrochloride market due to the increasing burden of cancer diseases and product advancements. The low cost of generic gemcitabine hydrochloride and reformulation strategies adopted by companies are among the other driving factor for market growth.

For instance, according to the American Cancer Society Inc., data published in 2022, in 2021, there were an estimated 1.9 million new cancer cases diagnosed in the United States. In addition, according to the Public Health Agency of Canada data published in October 2021, approximately 2 in 5 Canadians were diagnosed with Cancer in their lifetime. In 2021, an estimated 229,000 Canadians were diagnosed with Cancer. The report also mentioned that lung, breast, colorectal, and prostate cancers were expected to remain the most commonly diagnosed cancers, accounting for nearly 46% of all cancer diagnoses in 2021. Such a high prevalence of cancers in North American countries is expected to contribute to the market's growth.

In June 2022, Fujifilm announced that it had begun implementation of a phase 2 study in the United States to evaluate the safety, tolerability, and preliminary efficacy of FF-10832, a liposomal drug candidate, in combination therapy with Merck & Co Keytruda (pembrolizumab) for patients with advanced solid tumors. FF-10832 is a liposomal formulation that encapsulates gemcitabine, an approved anti-cancer agent indicated for the treatment of a variety of solid tumors.

Additionally, in April 2022, Tiziana Life Sciences announced filing an investigational new drug application and initiating a Phase 2 trial in KRAS (Kirsten rat sarcoma viral) + NSCLC (Non-small cell lung cancer) patients with a combination of milciclib + gemcitabine. The positive outcome of such clinical trials may lead to new treatment options, thereby increasing regional growth.

Gemcitabine Hydrochloride Market Competitor Analysis

The Gemcitabine Hydrochloride Market is fragmented and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Eli Lilly & Co., Accord Healthcare Inc., Pfizer Inc. (Hospira Inc.), Apotex Inc., Fresenius Kabi USA, Gland Pharma Ltd., Mylan Pharmaceuticals Inc., Sagent Pharmaceuticals Inc., Teva Pharmaceuticals Ltd., and Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Additional benefits of purchasing the report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cancer
4.2.2 Increasing Research & Development Activities
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product Type
5.1.1 Injection
5.1.2 Solution
5.2 By Indication
5.2.1 Breast Cancer
5.2.2 Non-small Cell Lung Cancer
5.2.3 Pancreatic Cancer
5.2.4 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Accord Healthcare Inc.
6.1.2 Apotex Inc.
6.1.3 Eli Lilly & Co.
6.1.4 Fressenius Kabi USA
6.1.5 Gland Pharma Ltd.
6.1.6 Jiangsu Hansoh Pharmaceutical Group Co Ltd
6.1.7 Mylan Pharmaceuticals Inc.
6.1.8 Pfizer Inc. (Hospira Inc.)
6.1.9 Sagent Pharmaceuticals Inc.
6.1.10 Teva Pharmaceuticals Ltd.
6.1.11 F. Hoffmann La Roche
6.1.12 Hebei Changsan Biochemical Pharmaceutical Co. Ltd

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Accord Healthcare Inc.
  • Apotex Inc.
  • Eli Lilly & Co.
  • Fressenius Kabi USA
  • Gland Pharma Ltd.
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Mylan Pharmaceuticals Inc.
  • Pfizer Inc. (Hospira Inc.)
  • Sagent Pharmaceuticals Inc.
  • Teva Pharmaceuticals Ltd.
  • F. Hoffmann La Roche
  • Hebei Changsan Biochemical Pharmaceutical Co., Ltd